H, M., A, N., A., T. (2018). Correlation Between of PET/CT and Molecular Subtypes and in Patients with Metastatic Breast Cancer.. test, 16(16), 27-45. doi: 10.21608/egyjnm.2018.46190
Moustafa, H; Nasr, A; Tawakol, A.. "Correlation Between of PET/CT and Molecular Subtypes and in Patients with Metastatic Breast Cancer.". test, 16, 16, 2018, 27-45. doi: 10.21608/egyjnm.2018.46190
H, M., A, N., A., T. (2018). 'Correlation Between of PET/CT and Molecular Subtypes and in Patients with Metastatic Breast Cancer.', test, 16(16), pp. 27-45. doi: 10.21608/egyjnm.2018.46190
H, M., A, N., A., T. Correlation Between of PET/CT and Molecular Subtypes and in Patients with Metastatic Breast Cancer.. test, 2018; 16(16): 27-45. doi: 10.21608/egyjnm.2018.46190

Correlation Between of PET/CT and Molecular Subtypes and in Patients with Metastatic Breast Cancer.

Egyptian Journal Nuclear Medicine
Article 3, Volume 16, Issue 16, June 2018, Pages 27-45    PDF (661.08 K)
Document Type: Original Article
DOI: 10.21608/egyjnm.2018.46190
Authors
Moustafa, H1; Nasr, A2; Tawakol, A.1
1Oncology and Nuclear Medicine Department, Cairo University, Egypt.
2Maadi Armed Force Hospital. Egypt.
Abstract
FDG PET/CT whole-body imaging has higher sensitivity, specificity and accuracy as compared to CT in detection of metastatic spread and follows up after treatment. The aim of this study: to assess of the impact of PET/CT in patients with metastatic breast cancer and monitoring the therapy response in relation to different molecular subtypes. Material and Methods: The study included 40 patients classified into 4 molecular subtypes; Luminal A like subtype (13 patients), Luminal B+ subtype (15 patients), Luminal B- subtype (4 patients) and Basal like subtype (8 patients). All patients with possible metastatic breast cancer performed PET-CT before treatment, while 34 patients perform PET-CT after the end oftherapy. Results: on lesion based analysis the total numbers of metastatic lesions in CT and bone scan were 120 lesions (49 in LNs, 24 in lung, 8 in liver; while 39 in bone). Metastatic lesions in PET/CT were 76 lesions (46 in LNs, 22 in lung and 8 in liver and 22 in bone). During follow up after therapy, the majority of luminal A group showed complete response to therapy during follow up PET/CT scan. Also, luminal B+ subgroup showed partial response. While most of basal-like subgroup showed progressive disease. Conclusion: PET/CT can detect metastatic spread in breast cancer and monitor therapy response in relation to different molecular subtypes. The mean SUV max showed relation to the different molecular subtypes.
Keywords
PET/CT; Molecular Subtypes and Metastatic Lesions
Statistics
Article View: 178
PDF Download: 263